Get the Stockscreener App
0.0647
7.57%
-0.0053
Adaptimmune Therapeutics Plc Adr stock is traded at $0.0647, with a volume of 46.22M.
It is down -7.57% in the last 24 hours and down -52.25% over the past month.
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
See More
Previous Close:
$0.07
Open:
$0.0705
24h Volume:
46.22M
Relative Volume:
0.43
Market Cap:
$17.15M
Revenue:
$175.04M
Net Income/Loss:
$-44.52M
P/E Ratio:
-0.3594
EPS:
-0.18
Net Cash Flow:
$-56.05M
1W Performance:
-67.67%
1M Performance:
-52.25%
6M Performance:
-75.73%
1Y Performance:
-91.37%
1-Day Range:
$0.062
$0.073
1-Week Range:
$0.0417
$0.0926
52-Week Range:
$0.0403
$0.86
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Name
Adaptimmune Therapeutics Plc Adr
Sector
Industry
Phone
44 1235 430000
Address
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Compare ADAP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.0647 | 18.55M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-30-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Outperform |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-09-22 | Upgrade | Mizuho | Neutral → Buy |
| May-28-21 | Initiated | Barclays | Underweight |
| Apr-22-20 | Initiated | Mizuho | Neutral |
| Aug-02-19 | Downgrade | Guggenheim | Buy → Neutral |
| May-31-19 | Initiated | ROTH Capital | Buy |
| May-30-19 | Resumed | Citigroup | Buy |
| May-07-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Mar-17-17 | Initiated | Wells Fargo | Market Perform |
| Oct-24-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Sep-30-16 | Initiated | Raymond James | Outperform |
| Feb-25-16 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | BofA/Merrill | Neutral |
| Jun-01-15 | Initiated | Guggenheim | Buy |
| Jun-01-15 | Initiated | Leerink Partners | Outperform |
View All
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Latest News
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Adaptimmune stock plunges after announcing Nasdaq delisting plans By Investing.com - Investing.com Philippines
Adaptimmune stock plunges after announcing Nasdaq delisting plans - Investing.com
Adaptimmune to delist from Nasdaq amid cost-cutting efforts - Investing.com
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Questex’s Fierce Pharma Week Announces Star-Studded Lineup with Jamie-Lynn Sigler, James Van Der Beek, Selma Blair, Kelly Killoran Bensimon and John Duffield to Provide Powerful Stories of Resilience and Healing - GlobeNewswire Inc.
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
KANZHUN LIMITED Sponsored ADR (BZ) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):